Dario C. Altieri

Dario C. Altieri is an Italian-American physician-scientist renowned for his pioneering research in cancer biology, particularly the role of mitochondria in tumorigenesis and therapy resistance. He serves as the President, Chief Executive Officer, and Director of the Wistar Institute in Philadelphia, a world-leading nonprofit biomedical research organization. His work has fundamentally advanced the understanding of how cancer cells evade apoptosis and reprogram their metabolism to support uncontrolled growth, identifying novel targets for cancer therapy.

Early life and education

Born in Italy, Altieri developed an early interest in medical science. He pursued his medical degree at the prestigious University of Bologna, one of the oldest universities in the world. Following his medical training, he specialized in pathology and completed a doctorate in experimental pathology at the University of Bari. His foundational education in Italy provided a strong grounding in both clinical medicine and basic research, which he later expanded through postdoctoral fellowships in the United States, focusing on immunology and cell biology.

Career and research

Altieri began his independent research career at the Yale University School of Medicine, where he rose to the rank of Professor. He later chaired the Department of Cancer Biology at the University of Massachusetts Medical School, significantly expanding its research portfolio. In 2015, he was appointed Director of the Wistar Institute's Cancer Center, and subsequently became the institution's President and CEO. His laboratory has been continuously funded by major agencies including the National Institutes of Health and the American Cancer Society. His research trajectory has consistently focused on dissecting the non-canonical functions of cellular organelles in malignancy.

Scientific contributions

Altieri's most impactful contributions center on the mitochondrial protein survivin and the molecular chaperone TRAP-1 (TNF receptor-associated protein 1). He discovered that survivin, a member of the Inhibitor of apoptosis family, is not only a critical regulator of cell division but also localizes to mitochondria to inhibit apoptosis in cancer cells. His team further elucidated how the mitochondrial chaperone TRAP-1 reprograms tumor metabolism toward a Warburg effect-like state, promoting chemoresistance. This work has defined a new paradigm of "mitochondrial priming" for apoptosis and identified the mitochondrial proteome as a rich source of targets for drugs like Gamitrinib. His findings have been published in leading journals such as Nature, Science, and Cell.

Awards and honors

In recognition of his transformative research, Altieri has received numerous prestigious awards. These include the American Association for Cancer Research (AACR)-Kirk A. Landon Award for Basic Cancer Research, a notable prize honoring significant laboratory-based discoveries. He has also been the recipient of the National Cancer Institute's Outstanding Investigator Award, which supports accomplished leaders in cancer research. His election as a Fellow of the American Association for the Advancement of Science further underscores his standing in the scientific community. He frequently presents his work at major international conferences, including the annual meeting of the American Society of Clinical Oncology.

Personal life

Altieri maintains a strong connection to his roots in Italy while being a long-time resident of the United States. He is known as a dedicated mentor who has trained many successful scientists now leading their own laboratories at institutions like the Mayo Clinic and Memorial Sloan Kettering Cancer Center. An avid supporter of interdisciplinary collaboration, he advocates for translating basic discoveries from the bench to the clinic, a mission central to the ethos of the Wistar Institute.

Category:American cancer researchers Category:Italian medical researchers Category:University of Bologna alumni Category:Yale University faculty